scholarly article | Q13442814 |
P356 | DOI | 10.1007/S00277-004-0977-1 |
P698 | PubMed publication ID | 15692838 |
P50 | author | Torsten Haferlach | Q66370751 |
Claudia Schoch | Q66370757 | ||
Ulrike Bacher | Q66370775 | ||
Susanne Schnittger | Q66370791 | ||
P2093 | author name string | Wolfgang Kern | |
Wolfgang Hiddemann | |||
P433 | issue | 4 | |
P921 | main subject | cytogenetics | Q246128 |
P304 | page(s) | 250-257 | |
P577 | publication date | 2005-02-04 | |
P1433 | published in | Annals of Hematology | Q15766509 |
P1476 | title | Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. | |
P478 | volume | 84 |
Q64988628 | A Novel Acquired t(2;4)(q36.1;q24) with a Concurrent Submicroscopic del(4)(q23q24) in An Adult with Polycythemia Vera. |
Q38089228 | Advances in molecular diagnostics of myeloproliferative disorders |
Q38012085 | Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management |
Q38130476 | Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management |
Q79241949 | Chronic myelomonocytic leukemia: The role of bone marrow biopsy immunohistology |
Q34405385 | Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation |
Q35162458 | Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution |
Q47908421 | Detection of mutations in JAK2 exons 12-15 by Sanger sequencing |
Q35849674 | Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model |
Q54351232 | Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression. |
Q26770330 | Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis |
Q38134374 | Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups |
Q37202615 | Minimal residual disease diagnostics in myeloid malignancies in the post transplant period |
Q37255020 | Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs). |
Q41609451 | Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia |
Q51822948 | Quantitative assay for Janus kinase 2 (JAK2) mutation in Chinese patients with chronic myeloproliferative disorders. |
Q28307278 | Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia |
Q37274983 | Significance of cytogenetic abnormalities in patients with polycythemia vera |
Q43057954 | Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia |
Q40170336 | Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report |
Q24675681 | The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers |
Q36967029 | Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia |
Search more.